首页|升血小板胶囊对肿瘤化疗相关性血小板减少症的疗效分析

升血小板胶囊对肿瘤化疗相关性血小板减少症的疗效分析

扫码查看
目的 探讨真实世界中升血小板胶囊用于治疗肿瘤化疗相关性血小板减少症(chemotherapy-induced thrombocytopenia,CIT)的人群特征及临床疗效,在广泛人群中使用的有效性、安全性,临床上联合用药合理性及不同联合用药间疗效差异.方法 采用回顾性研究,选取医院2 812例使用升血小板胶囊的肿瘤CIT患者信息,根据联合用药分4组,A治疗组1 522例(单用升血小板胶囊),B治疗组719例(联合重组人血小板生成素注射液),C治疗组786例(联合白介素11)以及D治疗组9例(联合海曲泊帕乙醇胺片).比较治疗前后血小板计数的变化情况、CIT分级.结果 与治疗前比较,A、B、C治疗组患者治疗结束后血小板计数均上升,差异具有统计学意义(P<0.001);不同治疗分期中,四组的CIT分级之间的差异均有统计学意义(p<0.05).结论 升血小板胶囊能显著改善肿瘤CIT血小板水平,尤其联合重组人血小板生成素注射液、白介素-11效果明显,总体安全性较好,值得临床推广应用.
Analysis of therapeutic effect of Sheng Xuexiaoban capsules on chemotherapy-related thrombocytopenia
Objective To investigate the population characteristics and clinical efficacy of Sheng Xuexiaoban capsules in the treatment of tumor chemotherapy-related thrombocytopenia(CIT)in the real word,and to observe its effectiveness and safety in a wide range of people,the rationality of clinical combination of drugs and the difference in efficacy of different combinations of drugs.Methods A retrospective study was conducted to select 2 812 CIT patients treated with Sheng Xuexiaoban capsules,and they were divided into four groups according to the combination of drugs,1 522 patients in treatment group A(Sheng Xuexiaoban capsules alone),719 patients in treatment group B(combined with recombinant human thrombopoietin injection),786 patients in treatment group C(combined with interleukin-11),and 9 patients in treatment group D(combined with hexapopethanolamine tablets).The changes of platelet count and CIT grade before and after the treatment were compared.Results Compared with before treatment,platelet counts in treatment groups A,B and C all increased after treatment,and the difference was statistically significant(P<0.001).In different treatment stages,the difference of CIT grading among the four groups was statistically significant(P<0.05).Conclusion Sheng Xuexiaoban capsules can significantly improve the platelet level of tumor chemotherapy-related thrombocytopenia,especially in combination with recombinant human thrombopoietin injection and interleukin-11,the overall safety is good,worthy of clinical promotion and application.

Sheng Xuexiaoban capsuleschemotherapy-induced thrombocytopeniareal world researchclinical efficacydrug combination

赵娟芝、刘春华、李景、梁嘉碧、朱风雷、罗文基

展开 >

中山大学附属第五医院药学部,广东珠海 519000

聊城市人民医院感染科,山东聊城 252000

江苏法迈生医学科技有限公司,江苏南京 210003

升血小板胶囊 化疗相关性血小板减少症 真实世界研究 临床疗效 联合用药

2024

世界临床药物
上海医药工业研究院

世界临床药物

CSTPCD
影响因子:0.849
ISSN:1672-9188
年,卷(期):2024.45(5)
  • 14